3[1]Opelz G. Influence of treatment with cyclosporine,azathio prine and steroi ds on chronic allograft failure. The Collaborative Transplant Study[J].Kidn ey Int,1995,52（Suppl）∶S89-S92. 被引量：1
4[2]Nicholls AJ.Opportunities for therapeutic drug monitoring of myco phenola te mofetil dose in renal transplantation suggested by the pharmacokinetic/pharma codynamic relationship for mycophenolic acid and suppression of rejection[J]. Clin Biochem,1998,31(5)∶329-333. 被引量：1
5[3]Meiser BM,Pfeiffer M,Jagiello-Kraatz M,et al. Mycophenolate mofetil dose adjustment based on trough levels improves outcome after heart transplantio n[J].J Heart Lung Transplant,1998,17(1)∶85-90. 被引量：1
6[4]Shaw LM,Nicholls A,Hale M,et al. Therapeutic monitoring of my cophenol ic acid: A consensus panel report[J].Clin Biochem,1998,31(5)∶317-322. 被引量：1
7[5]Zanker B,Schneeberger H,Rothenpieler U, et al. Mycophenolate mofetil -based,cyclosporin-free induction and maintenance immunosuppression[J].Tr ansplantation,1998,66(1)∶44-49. 被引量：1
8[6]Przepiorka D,Nash RA,Wingard JR,et al. Relationship of tacrol imus who le blood levels to efficacy and safety outcomes after unrelated donor marrow tra nsplantation[J].Biol Blood Marrow Transplant,1999,5(2)∶94-99. 被引量：1
9[7]McMaster P,Mirza DF,Ismail T,et al. Therapeutic drug monitori ng of ta crolimus in clinical transplantation[J].Ther Drug Monit, 1995,17(6)∶602 -605. 被引量：1
10[8]Zucker K,Tsaroucha A,Olson L,et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophen olic acid glucuronidation[J].Ther Drug Monit,1999,21(1)∶35-43. 被引量：1
1Medicines and Healthcare Products Regulatory Agency.Press release(10 June 2003)[OL].Available from URL:Http://www.mhragov.uk/news/2003/seroxat 10630.pdf. 被引量：1
